

Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1-93. (Cancelled).

94. (Presently Amended) A method for treating a mammal suffering from or susceptible to a disease ~~diseases~~ causing apoptosis of cells or apoptosis-like cell death ~~of cells, except for treatment of immune deficiency, comprising which comprises~~ administering to the mammal a composition comprising ginseng, ginseng extracts, or ginseng components, ~~ginseng~~ its metabolites; or salts thereof.

95-107. (Cancelled).

108. (New) The method according to claim 94, wherein the cells are nerve cells or neurons.

109. (New) The method according to claim 108, wherein the diseases causing apoptosis or apoptosis-like death of nerve cells or neurons is cerebral infarction or cerebral apoplexy.

110. (New) The method according to claim 108, wherein the diseases causing apoptosis or apoptosis-like death of nerve cells or neurons is edema.

111. (New) The method according to claim 108, wherein the edema is cerebral edema, edema of the brain and nervous tissues or edema of the spinal cord tissue.

112 (New) The method according to claim 94, wherein the cells are cardiomyocytes, cardiac cells, skin cells or skin keratinocytes.

113. (New) The method according to claim 112, wherein the diseases causing apoptosis or apoptosis-like death of cardiomyocytes, cardiac cells skin cells or skin keratinocytes is cardiac disease.

114. (New) The method according to claim 112, wherein the diseases causing apoptosis or apoptosis-like death of cardiomyocytes, cardiac cells skin cells or skin keratinocytes is skin senescence.

115. (New) The method according to any one of claims 108 to 111, wherein the composition comprises red ginseng powder and it is administered orally in a dose range of 94 mg/kg/day to 600 mg/kg/day.

116. (New) The method according to any one of claims 112 to 114, wherein the composition comprises red ginseng powder and it is administered orally in a dose range of 25 mg/kg/day to 100 mg/kg/day.

117. (New) The method according to any one of claims 108 to 111, wherein the composition comprises crude saponin fraction and it is administered intravenously in a dose range of 14.5 μ g/kg/day to 1450 μ g/kg/day.

118. (New) The method according to any one of claims 112 to 114, wherein the composition comprises crude saponin fraction and it is administered intravenously in a dose range of 145 pg/kg/day to 145 μ g/kg/day.

119. (New) The method according to any one of claims 108 to 111, wherein the composition comprises ginsenoside Rb₁ and it is administered intravenously in a dose range of 0.167 μ g/kg/day to 1.67 mg/kg/day.

120. (New) The method according to any one of claims 112 to 114, wherein the composition comprises ginsenoside Rb₁ and it is administered intravenously in a dose range of 1.67pg/kg/day to 1.67mg/kg/day.